No Data
Bai Ao Sai Tu-B (02315.HK): The localization deployment of the DeepSeek platform and the upgrade of the Global Strategy for the "thousand mice and ten thousand antibodies" antibody drug research and development.
Gelonghui February 28丨 BeiAoSaiTu-B (02315.HK) announced that the company has recently completed the localization deployment of its AI-driven antibody drug research and development platform DeepSeek, achieving comprehensive synergy with its core Business "Thousand Mice and Ten Thousand Antibodies" plan. This technology integration marks the advancement of the early-stage research and development of antibody drugs into a new phase of intelligence and data. In the future, it will provide Global pharmaceutical companies with more precise and groundbreaking antibody drug research and development solutions, greatly accelerating the drug research and development process. BeiAoSaiTu launched the "Thousand Mice and Ten Thousand Antibodies" plan in 2020.
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Bionics Group-B (02315.HK) announces a profit alert: the expected annual net income is approximately 20 million to 40 million yuan.
On January 27, Gelonghui reported that Baiao Saitu-B (02315.HK) announced that it expects the group's revenue for the year ending December 31, 2024, to be approximately RMB 0.9693 billion to RMB 0.9893 billion, an increase of about 35.2% to 38.0% year-on-year. The group expects its net income for the year ending December 31, 2024, to be approximately RMB 20 million to RMB 40 million, compared to a loss of about RMB 0.383 billion for the year ending December 31, 2023. The group expects its research and development expenses for the year ending December 31, 2024, to be approximately
BIOCYTOGEN-B: POSITIVE PROFIT ALERT
Express News | Biocytogen Announces Licensing of Fully Human Antibodies With Sotio to Develop Novel ADC Sot109 for Colorectal Cancer Treatment
Express News | Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload Adcs for Treating Complex Tumors
meowmeow66 : I dont think moomoo can order this IPO. you can ask customer service to double check.